Switch theme
Sign up to access all valuation multiples
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
2015
9
LTM Revenue $1.9M
LTM EBITDA -$17.0M
$59.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Iterum Therapeutics has a last 12-month revenue (LTM) of $1.9M and a last 12-month EBITDA of -$17.0M.
In the most recent fiscal year, Iterum Therapeutics achieved revenue of n/a and an EBITDA of -$21.7M.
Iterum Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Iterum Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $1.1M | XXX | -$0.3M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$17.0M | XXX | -$21.7M | XXX | XXX | XXX |
| EBITDA Margin | -879% | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$15.6M | XXX | -$18.7M | XXX | XXX | XXX |
| EBIT Margin | -809% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$20.6M | XXX | -$24.8M | XXX | XXX | XXX |
| Net Margin | -1068% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $21.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Iterum Therapeutics's stock price is $1.
Iterum Therapeutics has current market cap of $40.0M, and EV of $59.4M.
See Iterum Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59.4M | $40.0M | XXX | XXX | XXX | XXX | $-0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Iterum Therapeutics has market cap of $40.0M and EV of $59.4M.
Iterum Therapeutics's trades at n/a EV/Revenue multiple, and -2.7x EV/EBITDA.
Equity research analysts estimate Iterum Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Iterum Therapeutics has a P/E ratio of -1.9x.
See valuation multiples for Iterum Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $40.0M | XXX | $40.0M | XXX | XXX | XXX |
| EV (current) | $59.4M | XXX | $59.4M | XXX | XXX | XXX |
| EV/Revenue | 30.8x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | -2.7x | XXX | XXX | XXX |
| EV/EBIT | -3.8x | XXX | -3.2x | XXX | XXX | XXX |
| EV/Gross Profit | 56.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.9x | XXX | -1.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIterum Therapeutics's last 12 month revenue growth is 412%
Iterum Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $2.0M for the same period.
Iterum Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Iterum Therapeutics's rule of X is 151% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Iterum Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 412% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -879% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -49% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 151% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $2.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Iterum Therapeutics acquired XXX companies to date.
Last acquisition by Iterum Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Iterum Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Iterum Therapeutics founded? | Iterum Therapeutics was founded in 2015. |
| Where is Iterum Therapeutics headquartered? | Iterum Therapeutics is headquartered in United States of America. |
| How many employees does Iterum Therapeutics have? | As of today, Iterum Therapeutics has 9 employees. |
| Who is the CEO of Iterum Therapeutics? | Iterum Therapeutics's CEO is Mr. Corey N. Fishman. |
| Is Iterum Therapeutics publicy listed? | Yes, Iterum Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Iterum Therapeutics? | Iterum Therapeutics trades under ITRM ticker. |
| When did Iterum Therapeutics go public? | Iterum Therapeutics went public in 2018. |
| Who are competitors of Iterum Therapeutics? | Similar companies to Iterum Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Iterum Therapeutics? | Iterum Therapeutics's current market cap is $40.0M |
| What is the current revenue of Iterum Therapeutics? | Iterum Therapeutics's last 12 months revenue is $1.9M. |
| What is the current revenue growth of Iterum Therapeutics? | Iterum Therapeutics revenue growth (NTM/LTM) is 412%. |
| What is the current EV/Revenue multiple of Iterum Therapeutics? | Current revenue multiple of Iterum Therapeutics is 30.8x. |
| Is Iterum Therapeutics profitable? | Yes, Iterum Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Iterum Therapeutics? | Iterum Therapeutics's last 12 months EBITDA is -$17.0M. |
| What is Iterum Therapeutics's EBITDA margin? | Iterum Therapeutics's last 12 months EBITDA margin is -879%. |
| What is the current EV/EBITDA multiple of Iterum Therapeutics? | Current EBITDA multiple of Iterum Therapeutics is -3.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
